×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
XGN – exagen inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
XGN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/12
09:13 am
xgn
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD [Yahoo! Finance]
Medium
Report
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD [Yahoo! Finance]
12/12
09:00 am
xgn
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
Medium
Report
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
12/5
08:04 am
xgn
Mindera Health™ Welcomes New Vice President of Sales [Yahoo! Finance]
Low
Report
Mindera Health™ Welcomes New Vice President of Sales [Yahoo! Finance]
11/21
08:30 am
xgn
Innovative Clinical Biomarkers for SLE and RA: Advancing Autoimmune Diagnostics, Upcoming Webinar Hosted by Xtalks
High
Report
Innovative Clinical Biomarkers for SLE and RA: Advancing Autoimmune Diagnostics, Upcoming Webinar Hosted by Xtalks
11/14
04:37 pm
xgn
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform [Yahoo! Finance]
Low
Report
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform [Yahoo! Finance]
11/14
04:30 pm
xgn
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
Low
Report
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
11/13
04:05 pm
xgn
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
Medium
Report
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
11/13
08:36 am
xgn
Exagen Inc. (NASDAQ: XGN) had its "outperform" rating re-affirmed by analysts at William Blair.
Low
Report
Exagen Inc. (NASDAQ: XGN) had its "outperform" rating re-affirmed by analysts at William Blair.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
12/12
05:01 pm
xgn
Form SC 13G/A EXAGEN INC. Filed by: Hunt Holdings Limited Partnership
Low
Report
Form SC 13G/A EXAGEN INC. Filed by: Hunt Holdings Limited Partnership
11/27
04:19 pm
xgn
Form 4 EXAGEN INC. For: Nov 20 Filed by: NMSIC Co-Investment Fund, L.P.
Medium
Report
Form 4 EXAGEN INC. For: Nov 20 Filed by: NMSIC Co-Investment Fund, L.P.
11/19
07:25 pm
xgn
Form 4 EXAGEN INC. For: Nov 15 Filed by: Black Jeffrey G.
High
Report
Form 4 EXAGEN INC. For: Nov 15 Filed by: Black Jeffrey G.
11/18
06:32 pm
xgn
Form 4 EXAGEN INC. For: Nov 14 Filed by: ABALLI JOHN
High
Report
Form 4 EXAGEN INC. For: Nov 14 Filed by: ABALLI JOHN
11/12
09:35 am
xgn
Form 8-K EXAGEN INC. For: Nov 12
Medium
Report
Form 8-K EXAGEN INC. For: Nov 12
11/12
09:32 am
xgn
Form 10-Q EXAGEN INC. For: Sep 30
Medium
Report
Form 10-Q EXAGEN INC. For: Sep 30
10/8
04:40 pm
xgn
Form 144 EXAGEN INC. Filed by: Adawi Kamal
Low
Report
Form 144 EXAGEN INC. Filed by: Adawi Kamal
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/25
Form 10-K EXAGEN INC. For: Dec 31
37.4%
12/20 Do Hedge Funds Love Exagen Inc. (XGN)? [Yahoo! Finance News] 23.8%
1/27 Form SC 13G EXAGEN INC. Filed by: RTW INVESTMENTS, LP 13.5%
9/18 Form S-1MEF EXAGEN INC. 10.6%
3/27 Form 4 EXAGEN INC. For: Mar 11 Filed by: PALLARES EBETUEL 10.0%
4/18 Exagen Inc. (NYSE: XGN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. 6.5%
12/16 Is Affimed NV (AFMD) Going to Burn These Hedge Funds? [Yahoo! Finance News] 4.7%
10/21 Exagen to Be Honored with National Research Innovation Award by Lupus Foundation of America 3.9%
9/20 Form 424B4 EXAGEN INC. 2.6%
11/22 Exagen extends agreement with GSK for a third year to drive greater awareness about challenges facing lupus diagnosis and management 2.4%
12/20 Do Hedge Funds Love Exagen Inc. (XGN)? [Yahoo! Finance News] 23.8%
1/27 Form SC 13G EXAGEN INC. Filed by: RTW INVESTMENTS, LP 13.5%
9/18 Form S-1MEF EXAGEN INC. 10.6%
3/27 Form 4 EXAGEN INC. For: Mar 11 Filed by: PALLARES EBETUEL 10.0%
4/18 Exagen Inc. (NYSE: XGN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. 6.5%
12/16 Is Affimed NV (AFMD) Going to Burn These Hedge Funds? [Yahoo! Finance News] 4.7%
10/21 Exagen to Be Honored with National Research Innovation Award by Lupus Foundation of America 3.9%
9/20 Form 424B4 EXAGEN INC. 2.6%
11/22 Exagen extends agreement with GSK for a third year to drive greater awareness about challenges facing lupus diagnosis and management 2.4%
TOP News Decliners
2/18
Exagen to Present at Cowen and Company 40th Annual Healthcare Conference
-28.0%
3/16 Exagen Inc. Partners with Sonora Quest Laboratories to Offer AVISE Testing for Patients Suspected of Autoimmune Disease -27.7%
3/26 Form 3 EXAGEN INC. For: Mar 24 Filed by: Zack Debra -24.8%
3/11 Exagen to Announce Fourth Quarter and Year-End 2019 Financial Results on March 25, 2020 -13.3%
3/24 Exagen Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer, and Anja Kammesheidt, Ph.D., as Chief Scientific Officer -9.3%
2/7 Form SC 13G EXAGEN INC. Filed by: Hunt Holdings Limited Partnership -8.2%
11/21 Exagen Inc. Announces $26.2 Million Debt Refinancing -6.8%
4/29 Form DEF 14A EXAGEN INC. For: Apr 29 -6.6%
3/3 Exagen Inc. (NYSE: XGN) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $25.00 price target on the stock. -6.3%
12/20 Exagen Inc. (NYSE: XGN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -6.0%
3/16 Exagen Inc. Partners with Sonora Quest Laboratories to Offer AVISE Testing for Patients Suspected of Autoimmune Disease -27.7%
3/26 Form 3 EXAGEN INC. For: Mar 24 Filed by: Zack Debra -24.8%
3/11 Exagen to Announce Fourth Quarter and Year-End 2019 Financial Results on March 25, 2020 -13.3%
3/24 Exagen Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer, and Anja Kammesheidt, Ph.D., as Chief Scientific Officer -9.3%
2/7 Form SC 13G EXAGEN INC. Filed by: Hunt Holdings Limited Partnership -8.2%
11/21 Exagen Inc. Announces $26.2 Million Debt Refinancing -6.8%
4/29 Form DEF 14A EXAGEN INC. For: Apr 29 -6.6%
3/3 Exagen Inc. (NYSE: XGN) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $25.00 price target on the stock. -6.3%
12/20 Exagen Inc. (NYSE: XGN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -6.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: